Diltiazem Linked to Increased Risk for Bleeding Complications in A-Fib

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 4, 2026.

via HealthDay

WEDNESDAY, March 4, 2026 -- For patients with atrial fibrillation (AF) receiving apixaban or rivaroxaban, use of diltiazem versus metoprolol is associated with an increased risk for serious bleeding complications, according to a study published online Feb. 24 in the Annals of Internal Medicine.

Ghadeer K. Dawwas, Ph.D., from the Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues compared the risk for bleeding among AF patients using apixaban or rivaroxaban in combination with diltiazem versus metoprolol. A total of 23,000 users of diltiazem and 23,000 users of metoprolol were included in the matched cohort of AF patients.

The researchers found that diltiazem versus metoprolol was associated with a higher risk for bleeding events after propensity score matching (rate difference, 5.4 per 1,000 person-years). With high- versus low-dose diltiazem, the risk for bleeding increased (risk difference, 9.2 versus 2.6 for high- and low-dose, respectively). The estimated risk differences between diltiazem and metoprolol were 0.48 and 0.31 percentage points, respectively, at 12 and six months.

"Our examination of diltiazem dosages indicated a dose-dependent relationship, with higher doses associated with more bleeding," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-05 01:43

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords